0001213900-22-070146 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2022	Nov. 03, 2022
Document Information Line Items
Entity Registrant Name	DocGo Inc.
Trading Symbol	DCGO
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		102,826,671
Amendment Flag	false
Entity Central Index Key	0001822359
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39618
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2515483
Entity Address, Address Line One	35 West 35th Street
Entity Address, Address Line Two	Floor 6
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10001
City Area Code	(844)
Local Phone Number	443-6246
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance Sheet - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 169,598,749	$ 175,537,221
Accounts receivable, net of allowance of $7,376,957 and $7,377,389 as of September 30, 2022 and December 31, 2021, respectively	79,999,764	78,383,614
Prepaid expenses and other current assets	2,394,324	2,111,656
Total current assets	251,992,837	256,032,491
Property and equipment, net	17,577,830	12,733,889
Intangibles, net	20,647,790	10,678,049
Goodwill	34,533,363	8,686,966
Restricted cash	9,753,575	3,568,509
Operating lease right-of-use assets	8,185,547	4,195,682
Finance lease right-of-use assets	9,421,196	9,307,113
Equity method investment	712,718	589,058
Other assets	3,095,354	3,810,895
Total assets	355,920,210	309,602,652
Current liabilities:
Accounts payable	12,153,337	15,833,970
Accrued liabilities	38,558,074	35,110,877
Line of credit	1,025,881	25,881
Notes payable, current	680,703	600,449
Due to seller	9,802,238	1,571,419
Contingent consideration	4,000,000
Operating lease liability, current	2,059,278	1,461,335
Finance lease liability, current	2,858,968	3,271,990
Total current liabilities	71,138,479	57,875,921
Notes payable, non-current	1,456,105	1,302,839
Operating lease liability, non-current	6,406,246	2,980,946
Finance lease liability, non-current	6,086,521	6,867,420
Warrant liabilities		13,518,502
Total liabilities	85,087,351	82,545,628
Commitments and Contingencies
Common stock ($0.0001 par value; 500,000,000 shares authorized as of September 30, 2022 and December 31,2021; 102,824,878 and 100,133,953 shares issued and outstanding as of September 30, 2022 and December 31,2021, respectively	10,778	10,013
Additional paid-in-capital	301,522,213	283,161,216
Accumulated deficit	(37,036,937)	(63,556,714)
Accumulated other comprehensive loss	(276,213)	(32,501)
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries	264,219,841	219,582,014
Noncontrolling interests	6,613,018	7,475,010
Total stockholders’ equity	270,832,859	227,057,024
Total liabilities and stockholders’ equity	$ 355,920,210	$ 309,602,652

Condensed Consolidated Balance Sheet (Parentheticals) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance (in Dollars)	$ 7,376,957	$ 7,377,389
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	102,824,878	100,133,953
Common stock, shares outstanding	102,824,878	100,133,953

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue, net	$ 104,319,894	$ 85,838,988	$ 331,730,750	$ 197,394,379
Expenses:
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)	71,254,838	60,025,728	219,418,873	137,080,202
Operating expenses:
General and administrative	22,186,036	19,612,243	70,684,270	47,239,204
Depreciation and amortization	3,014,864	2,019,576	7,253,656	5,514,303
Legal and regulatory	2,200,964	813,204	6,610,223	2,646,573
Technology and development	1,373,146	854,618	3,663,299	1,980,899
Sales, advertising and marketing	90,856	994,401	2,348,917	3,029,182
Total expenses	100,120,704	84,319,770	309,979,238	197,490,363
Income (loss) from operations	4,199,190	1,519,218	21,751,512	(95,984)
Other income (expenses):
Interest income (expense), net	334,221	(255,711)	296,891	(500,849)
Gain/(loss) on remeasurement of warrant liabilities	(1,831,947)		1,137,070
Gain on initial equity method investments	93,371		99,840
Gain on remeasurement of finance leases			1,388,273
Gain from PPP loan forgiveness		142,667		142,667
Gain/(loss) on disposal of fixed assets	42,667		42,667	(27,730)
Other income	30,900		42,288
Total other (expense) income	(1,330,788)	(113,044)	3,007,029	(385,912)
Net income (loss) before income tax benefit (expense)	2,868,402	1,406,174	24,758,541	(481,896)
Income tax expense	(401,916)	(604,608)	(1,163,755)	(613,531)
Net income (loss)	2,466,486	801,566	23,594,786	(1,095,427)
Net loss attributable to noncontrolling interests	(687,944)	(2,705,954)	(2,924,992)	(1,278,363)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	3,154,430	3,507,520	26,519,778	182,936
Other comprehensive income
Foreign currency translation adjustment	248,283	69,193	252,854	171,846
Total comprehensive gain	$ 3,402,713	$ 3,576,713	$ 26,772,632	$ 354,782
Net income per share attributable to DocGo Inc. and Subsidiaries - Basic (in Dollars per share)	$ 0.03	$ 0.06	$ 0.26	$ 0
Weighted-average shares outstanding - Basic (in Shares)	98,960,538	58,388,866	100,725,697	58,388,866
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted (in Dollars per share)	$ 0.03	$ 0.04	$ 0.24	$ 0
Weighted-average shares outstanding - Diluted (in Shares)	107,403,135	83,701,783	109,168,293	83,701,783

Condensed Consolidated Statements of Stockholders’ Deficit - USD ($)	Series A Preferred Stock	Class A Common Stock	Class B Common Stock	Additional Paid-in- Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
Balance at Dec. 31, 2020				$ 142,346,852	$ (87,300,472)	$ (48,539)	$ 11,949,200	$ 66,947,041
Balance (in Shares) at Dec. 31, 2020	28,055	35,497	55,008
Effect of reverse acquisition
Effect of reverse acquisition (in Shares)	18,099,548	22,900,719	35,488,938
Conversion of share due to merger recapitalization		$ 7,649						7,649
Conversion of share due to merger recapitalization (in Shares)	(18,099,548)	(22,900,719)	(35,488,938)
Effect of reverse acquisition		$ 7,649		142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Effect of reverse acquisition (in Shares)		76,489,205
Share issued for services		$ 17						17
Share issued for services (in Shares)	266	171,608
Stock based compensation				391,534				391,534
Noncontrolling interest contribution							333,025	333,025
Foreign currency translation						7,998		7,998
Net income (loss) attributable to Noncontrolling interests							(320,632)	(320,632)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					(1,678,364)			(1,678,364)
Balance at Mar. 31, 2021		$ 7,666		142,738,386	(88,978,836)	(40,541)	11,961,593	65,688,268
Balance (in Shares) at Mar. 31, 2021	28,321	76,660,813
Balance at Dec. 31, 2020				142,346,852	(87,300,472)	(48,539)	11,949,200	66,947,041
Balance (in Shares) at Dec. 31, 2020	28,055	35,497	55,008
Acquisitions								271,194
Balance at Sep. 30, 2021		$ 7,666		143,289,262	(87,117,532)	123,307	10,760,917	67,063,620
Balance (in Shares) at Sep. 30, 2021	28,321	76,660,813
Balance at Mar. 31, 2021		$ 7,666		142,738,386	(88,978,836)	(40,541)	11,961,593	65,688,268
Balance (in Shares) at Mar. 31, 2021	28,321	76,660,813
Stock based compensation				370,000				370,000
Foreign currency translation						94,655		94,655
Net income (loss) attributable to Noncontrolling interests							1,748,223	1,748,223
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					(1,646,216)			(1,646,216)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries (in Shares)
Balance at Jun. 30, 2021		$ 7,666		143,108,386	(90,625,052)	54,114	13,709,816	66,254,930
Balance (in Shares) at Jun. 30, 2021	28,321	76,660,813
Stock based compensation				463,046				463,046
UK Ltd. Shares purchase				(280,772)			(242,945)	(523,717)
UK Ltd. Shares purchase (in Shares)
Fees associated with equity raise				(1,398)				(1,398)
Net income attributable to stockholders of Ambulnz, Inc. and Subsidiaries					3,507,520			3,507,520
Foreign currency translation						69,193		69,193
Net income (loss) attributable to Noncontrolling interests							(2,705,954)	(2,705,954)
Balance at Sep. 30, 2021		$ 7,666		143,289,262	(87,117,532)	123,307	10,760,917	67,063,620
Balance (in Shares) at Sep. 30, 2021	28,321	76,660,813
Balance at Dec. 31, 2021		$ 10,013		283,161,216	(63,556,714)	(32,501)	7,475,010	227,057,024
Balance (in Shares) at Dec. 31, 2021		100,133,953
Exercise of stock options		$ 195		374,149				374,344
Exercise of stock options (in Shares)		195,152
Stock based compensation				1,422,937				1,422,937
Equity cost				(19,570)				(19,570)
Noncontrolling interest contribution							2,063,000	2,063,000
Foreign currency translation						(5,863)		(5,863)
Net income (loss) attributable to Noncontrolling interests							(1,257,257)	(1,257,257)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					10,629,694			10,629,694
Balance at Mar. 31, 2022		$ 10,208		284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022		100,329,105
Balance at Dec. 31, 2021		$ 10,013		283,161,216	(63,556,714)	(32,501)	7,475,010	$ 227,057,024
Balance (in Shares) at Dec. 31, 2021		100,133,953
Cashless exercise of options (in Shares)								1,637,159
Acquisitions								$ 819,231
Balance at Sep. 30, 2022		$ 10,778		301,522,213	(37,036,937)	(276,213)	6,613,018	270,832,859
Balance (in Shares) at Sep. 30, 2022		102,824,878
Balance at Mar. 31, 2022		$ 10,208		284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022		100,329,105
Common stock repurchased		$ (70)		(497,829)				(497,899)
Common stock repurchased (in Shares)		(70,000)
UK Ltd. Restricted Stock		$ 8		82,297				82,305
UK Ltd. Restricted Stock (in Shares)		8,258
Exercise of stock options		$ 418		778,648				779,066
Exercise of stock options (in Shares)		417,927
Stock based compensation				1,999,619				1,999,619
Foreign currency translation						10,434		10,434
Net income (loss) attributable to Noncontrolling interests							(979,791)	(979,791)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					12,735,653			12,735,653
Balance at Jun. 30, 2022		$ 10,564		287,301,467	(40,191,367)	(27,930)	7,300,962	254,393,696
Balance (in Shares) at Jun. 30, 2022		100,685,290
Common stock repurchased
Cashless exercise of options		$ 35		(354)				(319)
Cashless exercise of options (in Shares)		354,276
UK Ltd. Restricted Stock				95,543				95,543
Share warrants conversion		$ 141		12,381,432				12,381,573
Share warrants conversion (in Shares)		1,406,371
Acquisitions
Exercise of stock options		$ 38		728,465				728,503
Exercise of stock options (in Shares)		378,941
Stock based compensation				1,015,660				1,015,660
Foreign currency translation						(248,283)		(248,283)
Net income (loss) attributable to Noncontrolling interests							(687,944)	(687,944)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries					3,154,430			3,154,430
Balance at Sep. 30, 2022		$ 10,778		$ 301,522,213	$ (37,036,937)	$ (276,213)	$ 6,613,018	$ 270,832,859
Balance (in Shares) at Sep. 30, 2022		102,824,878

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 23,594,786	$ (1,095,427)
Adjustments to reconcile net income to net cash
Depreciation of property and equipment	2,592,244	1,697,380
Amortization of intangible assets	2,269,423	1,432,983
Amortization of finance lease right-of-use assets	2,391,989	2,383,940
(Gain) Loss on disposal of assets	(42,667)	27,730
Gain from PPP loan forgiveness		(142,667)
Gain from equity method investment	(99,840)
Bad debt expense	2,702,979	2,152,470
Stock based compensation	4,616,056	1,224,580
Gain on remeasurement of finance leases	(1,388,273)
Gain on remeasurement of warrant liabilities	(1,137,070)
Changes in operating assets and liabilities:
Accounts receivable	2,894,650	(28,794,602)
Prepaid expenses and other current assets	(282,668)	(4,531,411)
Other assets	882,432	(1,786,407)
Accounts payable	(3,983,383)	9,422,628
Accrued liabilities	2,596,887	24,861,804
Net cash provided by operating activities	37,607,545	6,853,001
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(1,994,161)	(2,824,916)
Acquisition of intangibles	(1,956,434)	(1,571,959)
Acquisition of businesses	(33,843,373)	(56,496)
Proceeds from disposal of property and equipment		6,000
Net cash used in investing activities	(37,793,968)	(4,447,371)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line	1,000,000	8,000,000
Repayments of notes payable	(585,711)	(374,456)
Due to seller	(1,007,800)
Noncontrolling interest contributions	2,063,000	333,025
Proceeds from exercise of stock options	1,880,568
Common stock repurchased	(497,759)
Equity costs	(19,570)
Payments on obligations under finance lease	(2,146,857)	(1,830,823)
Net cash provided by financing activities	685,871	6,127,746
Effect of exchange rate changes on cash and cash equivalents	(252,854)	171,846
Net increase in cash and restricted cash	246,594	8,705,222
Cash and restricted cash at beginning of period	179,105,730	34,457,273
Cash and restricted cash at end of period	179,352,324	43,162,495
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	102,203	39,637
Cash paid for interest on finance lease liabilities	434,580	381,937
Cash paid for income taxes	917,445	613,531
Right-of-use assets obtained in exchange for lease liabilities	4,094,731	3,569,276
Fixed assets acquired in exchange for notes payable	819,231	271,194
Acquisition of remaining 20% of Ambulnz UK LTD		228,518
Gain from PPP loan forgiveness		142,667
Reconciliation of cash and restricted cash
Cash	169,598,749	39,550,926
Restricted Cash	9,753,575	3,611,569
Total cash and restricted cash shown in statement of cash flows	$ 179,352,324	$ 43,162,495

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Cash Flows [Abstract]
Acquisition of remaining	20.00%	20.00%

Description of Organization and Business Operations

9 Months Ended

Sep. 30, 2022

Description of Organization and Business Operations [Abstract]

Description of Organization and Business Operations

1. Description of Organization and Business Operations

The Business

On November 5, 2021 (the “Closing Date”), DocGo Inc., a Delaware corporation (formerly known as Motion Acquisition Corp) (prior to the Closing Date, “Motion” and after the Closing Date, “DocGo”), consummated the previously announced business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger dated March 8, 2021 (the “Merger Agreement”), by and among Motion Acquisition Corp., a Delaware corporation (“Motion”), Motion Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of Motion (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”). In connection with the Closing, the registrant changed its name from Motion Acquisition Corp. to DocGo Inc.

As contemplated by the Merger Agreement and as described in Motion’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021 (the “Prospectus”), Merger Sub was merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). As a result of the Merger, Ambulnz is a wholly-owned subsidiary of DocGo and each share of Series A preferred stock of Ambulnz, no par value (“Ambulnz Preferred Stock”), Class A common stock of Ambulnz, no par value (“Ambulnz Class A Common Stock”), and Class B common stock of Ambulnz, no par value (“Ambulnz Class B Common Stock,” together with Ambulnz Class A Common Stock, “Ambulnz Common Stock”) was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value $0.0001 (“Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement.

In connection with the Business Combination, DocGo raised $158.0 million of net proceeds. This amount was comprised of $43.4 million of cash held in Motion’s trust account from its initial public offering, net of DocGo’s transaction costs and underwriters’ fees of $9.6 million, and $114.6 million of cash in connection with the PIPE Financing. The transaction costs consisted of banking, legal, and other professional fees, which were recorded as a reduction to additional paid-in capital.

The Business

DocGo Inc. and its Subsidiaries (collectively, the “Company”) is a healthcare transportation and mobile health services (“Mobile Health”) company that uses proprietary dispatch and communication technology to provide quality healthcare transportation and healthcare services in major metropolitan cities in the United States (“U.S.”) and the United Kingdom (“U.K.”). Mobile Health performs in-person care directly to patients in the comfort of their homes, workplaces and other non-traditional locations.

Ambulnz, LLC was originally formed in Delaware on June 17, 2015, as a limited liability company. On November 1, 2017, with an effective date of January 1, 2017, Ambulnz converted its legal structure from a limited liability company to a C-corporation and changed its name to Ambulnz, Inc. Ambulnz is the sole owner of Ambulnz Holdings, LLC (“Holdings”) which was formed in the state of Delaware on August 5, 2015, as a limited liability company. Holdings is the owner of multiple operating entities incorporated in various states in the U.S. as well as within England and Wales, U.K.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021.

The Consolidated Balance Sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP.

The Unaudited Condensed Consolidated Financial Statements include the accounts and operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI”) on the Unaudited Condensed Consolidated Financial Statements represent a portion of consolidated joint ventures and a variable interest entity in which the Company does not have direct equity ownership. Accounts and transactions between consolidated entities have been eliminated. Certain amounts in the prior years’ consolidated statements of changes in stockholders’ equity and statements of cash flows have been reclassified to conform to the current year presentation.

Pursuant to the Business Combination, the merger between Motion and Ambulnz, Inc. was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Motion was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz, Inc. stock for the net assets of Motion, accompanied by a recapitalization. The net assets of Motion are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz, Inc. The shares and corresponding capital amounts and earnings per share available for common stockholders, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz, Inc. was determined to be the accounting acquirer in the transaction, as such, the acquisition is considered a business combination under Accounting Standards Codification (“ASC”), Topic 805, Business Combinations, (“ASC 805”) and was accounted for using the acquisition method of accounting.

Principles of Consolidation

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of DocGo Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in these Unaudited Condensed Consolidated Financial Statements.

The Company holds a variable interest in MD1 Medical Care P.C. (“MD1”) which contracts with physicians and other health professionals in order to provide services to the Company. MD1 is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of MD1 and funds and absorbs all losses of the VIE and appropriately consolidates MD1.

Net loss for the VIE was $207,368 and $321,079 as of September 30, 2022 and 2021, respectively. The VIE’s total assets, all of which were current, amounted to $301,503 and $220,081 on September 30, 2022 and 2021, respectively. Total liabilities, all of which were current for the VIE, was $933,977 on September 30, 2022. The VIE’s total stockholders’ deficit was $632,474 and $30,914 on September 30, 2022 and 2021, respectively.

Foreign Currency

The Company’s functional currency is the U.S. dollar. The functional currency of our foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date, except for equity accounts which are translated at historical rates. The Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment is not material to the financial statements.

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition related to the allowance for doubtful accounts, stock based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserve for losses within the Company’s insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.

Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Concentration of Credit Risk and Off-Balance Sheet Risk

The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.

Major Customers

The Company has one customer that accounted for approximately 33% of sales and 35% of net accounts receivable, and another customer that accounted for 11% of sales and 0.1% of net accounts receivable for the nine month period ended September 30, 2022.

The Company has one customer that accounted for approximately 44% of sales and 42% of net accounts receivable for the nine month period ended September 30, 2021. The Company expects to maintain these relationships with the above-referenced customers.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the U.S. The accounts at financial institutions in the U.S. are insured by the Federal Deposit Insurance Corporation (“FDIC”) and are in excess of FDIC limits. The Company had cash balances of approximately $433,000 and $913,000 with foreign financial institutions on September 30, 2022 and December 31, 2021, respectively.

Restricted Cash and Insurance Reserves

Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Condensed Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for its line of credit, transportation equipment leases and a standby letter of credit as required by its insurance carrier (see Notes 8 and 13).

The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits.

ARM Insurance, Inc. a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.

The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in “Restricted cash” in the accompanying Condensed Consolidated Balance Sheets.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2022 and December 31, 2021. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses, and due to seller, the carrying amounts approximate their fair values as it is short term in nature. The notes payable are presented at their carrying value, which based on borrowing rates currently available to the Company for loans with similar terms, approximates its fair values.

Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Future changes in fair value of the contingent financial milestone consideration, as a result of changes in significant inputs such as the discount rate and estimated probabilities of financial milestone achievements, could have a material effect on the statement of operations and balance sheet in the period of the change.

During the three months ended September 30, 2022, the Company recorded $4.0 million of contingent consideration in connection with the Ryan Brothers Atkinson, LLC business acquisition, to be paid based on the completion of certain performance obligations over a 24-month period (see Note 4).

Accounts Receivable

The Company contracts with hospitals, healthcare facilities, businesses, state and local government entities, and insurance providers to transport patients and to provide Mobile Health services at specified rates. Accounts receivable consist of billings for transportation and healthcare services provided to patients. The billings will either be paid or settled on the patient’s behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs, businesses, or patients directly. Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time of billing based on contractual terms or other arrangements. Accounts receivable are periodically evaluated for collectability based on past credit history with payors and their current financial condition. Changes in the estimated collectability of accounts receivable are recorded in the results of operations for the period in which the estimate is revised. Accounts receivable deemed uncollectible are offset against the allowance for uncollectible accounts. The Company generally does not require collateral for accounts receivable.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows:

Asset Category		Estimated Useful Life
Buildings		39 years
Office equipment and furniture		3 years
Vehicles		2-8 years
Medical equipment		2-5 years
Leasehold improvements		Shorter of useful life of asset or lease term

Expenditures for repairs and maintenance are expensed as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.

Software Development Costs

Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software. Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life.

Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.

Business Combinations

The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including NCI, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.

The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Impairment of Long-Lived Assets

The Company evaluates the recoverability of the recorded amount of long-lived assets, primarily property and equipment and finite-lived intangible assets, whenever events or changes in circumstance indicate that the recorded amount of an asset may not be fully recoverable. An impairment is assessed when the undiscounted expected future cash flows derived from an asset are less than its carrying amount. If an asset is determined to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. Assets targeted for disposal are reported at the lower of the carrying amount or fair value less cost to sell. For the periods ending September 30, 2022 and December 31, 2021, management determined that there was no impairment loss required to be recognized for the carrying value of long-lived assets.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess of the purchase price of an acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and indefinite-lived intangible assets, consisting primarily of operating licenses, are not amortized, but are evaluated for impairment on an annual basis, or on an interim basis when events or changes in circumstances indicate that the carrying value may not be recoverable. In assessing the recoverability of goodwill and indefinite-lived intangible assets, the Company makes assumptions regarding the estimated future cash flows, including forecasted revenue growth, projected gross margin and the discount rate to determine the fair value of these assets. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges against these assets in the reporting period in which the impairment is determined.

The Company tests goodwill for impairment at the reporting unit level, which is one level below the operating segment. The Company has the option of performing a qualitative assessment to determine whether further impairment testing is necessary before performing the one-step quantitative assessment. If as a result of the qualitative assessment, it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, a quantitative impairment test will be required. Otherwise, no further testing will be required. If a quantitative impairment test is performed, the Company compares the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. Estimating the fair value of the reporting units requires significant judgment by management. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, goodwill impairment is recognized.

Any excess in carrying value over the estimated fair value is recorded as impairment loss and charged to the results of operations in the period such determination is made. For the periods ended September 30, 2022 and 2021, management determined that there was no impairment loss required to be recognized in the carrying value of goodwill or other intangible assets. The Company selected December 31 as its annual testing date.

Line of Credit

The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates its financial instruments to determine if such instruments contain features that qualify as embedded derivatives.

Related Party Transactions

The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, and members of immediate families of principal owners or management, other parties with which the Company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Related party transactions are recorded within operating expenses in the Company’s Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the periods ended September 30, 2022 and 2021, refer to Note 15.

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”), as amended.

To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) ambulance and medical transportation services (“Transportation Services”) and (2) Mobile Health services. The customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. Revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowances at the time of billing based on contractual terms, historical collections, or other arrangements. All transaction prices are fixed and determinable, which includes a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payer.

Nature of Our Services

Revenue is primarily derived from:

Transportation Services: These services encompass both emergency response and non-emergency ambulance transport services. Net revenue from transportation services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.

ii.

Mobile Health Services: These services include services performed at home and offices, testing and vaccinations, and event services which include on-site healthcare support at sporting events and concerts.

The Company concluded that Transportation Services and any related support activities are a single performance obligation under ASC 606. The transaction price is determined by the fixed rate usage-based fees or fixed fees which are agreed upon in the Company’s executed contracts. For Mobile Health, the performance of the services and any related support activities are a single performance obligation under ASC 606. Mobile Health services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized.

As the performance associated with such services is known and quantifiable at the end of a period in which the services occurred (i.e., monthly or quarterly), revenues are typically recognized in the respective period performed. The typical billing cycle for Transportation Services and Mobile Health services is same day to 5 days with payments generally due within 30 days. For large municipal customers in the Mobile Health segment, invoices are generally produced on a monthly basis, in arrears, and are generally due within 30-60 days of when they are submitted to the customer. For Transportation Services, the Company estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company’s Transportation Services and Mobile Health services each represent a single performance obligation. Therefore, allocation is not necessary as the transaction price (fees) for the services provided is standard and explicitly stated in the contractual fee schedule and/or invoice. The Company monitors and evaluates all contracts on a case-by-case basis to determine if multiple performance obligations are present in a contractual arrangement.

For Transportation Services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For Transportation Services, where the customer pays fixed rate usage-based fees, the actual usage in the period represents the best measure of progress. Generally, for Mobile Health services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For certain Mobile Health services that have a fixed fee arrangement, and the services are provided over time, revenue is recognized over time as the services are provided to the customer.

In the following table, revenue is disaggregated as follows:

Revenue Breakdown	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Primary Geographical Markets
United States	$	101,337,899	$	83,286,509	$	322,706,143	$	190,595,217
United Kingdom		2,981,995		2,552,479		9,024,607		6,799,162
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Major Segments/Service Lines
Transportation Services	$	27,670,109	$	17,916,162	$	77,657,852	$	65,657,141
Mobile Health		76,649,785		67,922,826		254,072,898		131,737,238
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Stock Based Compensation

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company accounts for forfeitures as they occur. All stock-based compensation costs are recorded in operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income.

Earnings per Share

Earnings per share represents the net income attributable to stockholders divided by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting periods. Potential dilutive common stock equivalents consist of the incremental common stock issuable upon exercise of warrants and the incremental shares issuable upon conversion of stock options. In reporting periods in which the Company has a net loss, the effect is considered anti-dilutive and excluded from the diluted earnings per share calculation.

Equity Method Investment

On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. (“RND”) for $655,876. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the Condensed Consolidated Balance Sheets. Changes in value of RND are recorded in “Gain from equity method investment” on the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions.

On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC (“NPA”) for $30,000. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the Condensed Consolidated Balance Sheets. Changes in value of NPA are recorded in “Loss from equity method investment” on the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions. Effective December 21, 2021, three members withdrew from NPA resulting in the remaining two members obtaining the remaining ownership percentage. On December 31, 2021 and September 30, 2022, DocGo owned 50% of NPA.

Under the equity method, the Company’s investment is initially measured at cost and subsequently increased or decreased to recognize the Company’s share of income and losses of the investee, capital contributions and distributions and impairment losses. The Company performs a qualitative assessment annually and recognizes an impairment if there are sufficient indicators that the fair value of the investment is less than carrying value.

Leases

The Company categorizes leases at its inception as either operating or finance leases based on the criteria in FASB ASC 842, Leases, (“ASC 842”). The Company adopted ASC 842 on January 1, 2019, using the modified retrospective approach, and has established a Right-of-Use (“ROU”) Asset and a current and non-current lease liability for each lease arrangement identified. The lease liability is recorded at the present value of future lease payments discounted using the discount rate that approximates the Company’s incremental borrowing rate for the lease established at the commencement date, and the ROU asset is measured as the lease liability plus any initial direct costs, less any lease incentives received before commencement. The Company recognizes a single lease cost, so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis.

The Company has lease arrangements for vehicles, equipment, and facilities. These leases typically have original terms not exceeding 10 years and, in some cases contain multi-year renewal options, none of which are reasonably certain of exercise. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as short-term leases.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

Recently Issued Accounting Standards Not Yet Adopted

None

Property and Equipment, net

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

Property and Equipment, net

3. Property and Equipment, net

Property and equipment, net, as of September 30, 2022 and December 31, 2021 are as follows:

	September 30, 2022			December 31, 2021

Office equipment and furniture	$	2,749,874		$	1,977,808
Buildings		527,283			527,284
Land		37,800			37,800
Transportation equipment		18,477,444			13,772,251
Medical equipment		5,764,863			3,949,566
Leasehold improvements		609,226			616,446
		28,166,490			20,881,155
Less: Accumulated depreciation		(10,588,660	)		(8,147,266	)
Property and equipment, net	$	17,577,830		$	12,733,889

The Company recorded depreciation expense of $1,150,806 and $598,188 for the three months ended September 30, 2022 and 2021, respectively.

The Company recorded depreciation expense of $2,592,244 and $1,697,380 for nine months ended September 30, 2022 and 2021, respectively.

Acquisition of Businesses

9 Months Ended

Sep. 30, 2022

Business Combinations [Abstract]

Acquisition of Businesses

4. Acquisition of Businesses

Government Medical Services, LLC

On July 6, 2022, Holdings, acquired 100% of the outstanding shares of common stock of Government Medical Services, LLC (“GMS”), a provider of medical services. The aggregate purchase price consisted of $20.3 million in cash consideration. Holdings also agreed to pay GMS an additional $3.0 million upon GMS meeting certain performance conditions within a year of the Closing Date. Acquisition costs are included in general and administrative expenses and totaled $0 for the three months ended September 30, 2022 and $800,000 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of GMS from the date of acquisition. The historical results of operations of GMS were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to GMS’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of GMS will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

Exceptional Medical Transportation, LLC

On July 13, 2022, the Company acquired 100% of the outstanding shares of common stock of Exceptional Medical Transportation, LLC (“Exceptional”) in exchange for $13.7 million consisting of $7.7 million in cash at closing and $6 million payable over a 24 month period. Exceptional is in the business of providing medical transportation services. Acquisition costs are included in general and administrative expenses totaled $0 for the three months ended September 30, 2022 and $0 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of Exceptional from the date of acquisition. The historical results of operations of Exceptional were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to Exceptional’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of Exceptional will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

Ryan Brothers Fort Atkinson, LLC

On August 9, 2022, the Company acquired 100% of the outstanding shares of common stock of Ryan Brothers Fort Atkinson, LLC (“RT”) in exchange for $11.4 million consisting of $7.4 million in cash at closing and $4.0 million of estimated contingent consideration to be paid out over 24 months based on performance of certain obligations. RT is in the business of providing medical transportation services. Acquisition costs are included in general and administrative expenses totaled $0 for the three months ended September 30, 2022 and $0 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of RT from the date of acquisition. The historical results of operations of RT were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to RT’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of RT will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

The following table presents the preliminary allocation of the assets acquired and liabilities assumed:

	Ryan Brothers		Exceptional Medical Transport		GMS		Total

Consideration:
Cash Consideration	$	7,422,252	$	6,375,000	$	20,338,789	$	34,136,041
Due to Seller		-		6,000,000		-		6,000,000
Contingent Consideration		4,000,000		-		-		4,000,000
Amounts held under an escrow account		-		1,333,333		-		1,333,333
Total consideration		11,422,252		13,708,333		20,338,789		45,469,374

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	620,548	$	299,050	$	1,005,453	$	1,925,051
Accounts receivable		-		-		3,975,160		3,975,160
Other current assets		136,157		-		30,734		166,891
Property, plant and equipment		2,125,134		2,450,900		4,092		4,580,126
Intangible assets		387,550		125,000		9,794,000		10,306,550
Total identifiable assets acquired		3,269,389		2,874,950		14,809,439		20,953,778

Accounts payable		44,911		-		137,239		182,150
Due to Seller		-		299,050		-		299,050
Other current liabilities		286,792		-		562,809		849,601
Total liabilities assumed		331,703		299,050		700,048		1,330,801

Goodwill		8,484,566		11,132,433		6,229,398		25,846,397

Total purchase price	$	11,422,252	$	13,708,333	$	20,338,789	$	45,469,374

Goodwill

9 Months Ended

Sep. 30, 2022

Goodwill [Abstract]

Goodwill

5. Goodwill

The Company recorded goodwill in connection with its acquisitions. The changes in the carrying value of goodwill for the period ended September 30, 2022 are as noted in the tables below:

	Carrying Value
Balance at December 31, 2021	$	8,686,966
Goodwill acquired during the period		25,846,397
Balance at September 30, 2022		34,533,363

Intangibles

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles

6. Intangibles

Intangible assets consist of the following as of September 30, 2022 and December 31, 2021:

	September 30, 2022
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	48,668	$	13,655	$	(9,075	)	$	53,248
Computer software	5 years	$	294,147		11,144		(263,192	)	$	42,099
Operating licenses	Indefinite	$	8,375,514		450,200		-		$	8,825,714
Internally developed software	4-5 years	$	6,013,513		1,907,616		(5,778,894	)	$	2,142,235
Material Contracts	Indefinite		-		62,550		-			62,550
Customer Relationship	9 years		-		9,794,000		(272,056	)	$	9,521,944
		$	14,731,842	$	12,239,165	$	(6,323,217	)	$	20,647,790

	December 31, 2021
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	19,275	$	29,393	$	(6,367	)	$	42,301
Computer software	5 years		132,816		161,331		(219,388	)		74,759
Operating licenses	Indefinite		8,375,514		-		-			8,375,514
Internally developed software	4-5 years		2,146,501		3,867,012		(3,828,038	)		2,185,475
		$	10,674,106	$	4,057,736	$	(4,053,793	)	$	10,678,049

The Company recorded amortization expense of $990,345 and $552,999 for the three months ended September 30, 2022 and 2021, respectively.

The Company recorded amortization expense of $2,269,423 and $1,432,983 for the nine months ended September 30, 2022 and 2021, respectively.

Future amortization expense at September 30, 2022 for the next five years and in the aggregate are as follows:

	Amortization Expense
2022, remaining	$	680,930
2023		2,078,406
2024		1,510,563
2025		1,460,965
2026		1,094,588
Thereafter		4,934,074
Total	$	11,759,526

Amortization expense
As of September 30, 2022			2,269,423
As of September 30, 2021			1,432,983
As of December 31, 2021			1,845,193

Accrued Liabilities

9 Months Ended

Sep. 30, 2022

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following as of September 30, 2022 and December 31, 2021:

	September 30, 2022		December 31, 2021
Accrued bonus	$	496,660	$	7,260,456
Accrued lab fees		1,363,138		4,885,539
Accrued payroll		7,068,616		3,539,301
Medicare advance		-		975,415
FICA/Medicare liability		759,232		739,629
Accrued general expenses		7,393,906		3,497,418
Accrued subcontractors		11,259,341		9,564,833
Accrued fuel and maintenance		310,064		450,842
Accrued workers compensation		5,465,030		2,259,571
Other current liabilities		12,259		736,021
Accrued legal fees		2,447,997		1,143,629
Accrued insurance liabilities		1,840,420		-
Credit card payable		141,411		58,223
Total accrued liabilities	$	38,558,074	$	35,110,877

Line of Credit

9 Months Ended

Sep. 30, 2022

Line of Credit Facility [Abstract]

Line of Credit

8. Line of Credit

On December 17, 2021, Ambulnz-FMC North America, LLC (“FMC NA”), entered into a revolving loan and bridge credit and security agreement with a subsidiary of one of its members with a maximum revolving advance amount of $12,000,000. Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (6.25% at September 30, 2022), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period. The agreement is subject to certain financial covenants such as an unused fee, whereas the Company shall pay to the subsidiary of one of its members an unused fee in the amount of 0.5% of the average daily amount by which the Revolving Commitment Amount ($12 million) exceeds the principal balance of the aggregate outstanding advances. All accrued and unpaid interest and unused fee shall be due and payable on the first anniversary of the date of the agreement (“Revolving Credit Maturity Date”). This loan is secured by all assets of entities owned 100% by DocGo Inc. As of December 31, 2021, the outstanding balance of the line of credit was zero. On January 26, 2022, the Company drew $1,000,000 to fund operations and meet short-term obligations. As of September 30, 2022, the outstanding balance of the line of credit was $1,000,000.

Notes Payable

9 Months Ended

Sep. 30, 2022

Notes Payable [Abstract]

Notes Payable

9. Notes Payable

The Company has various loans with finance companies with monthly installments aggregating $64,855, inclusive of interest ranging from 2.5% through 8%. The notes mature at various times through 2051 and are secured by transportation equipment.

The following table summarizes the Company’s notes payable:

	September 30, 2022		December 31, 2021
Equipment and financing loans payable, between 2.5% and 8% interest and maturing between January 2022 and May 2051	$	2,136,808	$	1,903,288
Loan received pursuant to the Payroll Protection Program Term Note		-		-
Total notes payable		2,136,808		1,903,288
Less: current portion of notes payable	$	680,703	$	600,449
Total non-current portion of notes payable	$	1,456,105	$	1,302,839

Interest expense was $69,804 and $61,324 for the periods ended September 30, 2022 and December 31, 2021, respectively.

Future minimum annual maturities of notes payable as of September 30, 2022 are as follows:

	Notes Payable
2022, remaining		137,959
2023		582,722
2024		446,812
2025		386,785
2026		311,769
Thereafter		270,761
Total maturities	$	2,136,808
Current portion of notes payable		(680,703	)
Long-term portion of notes payable	$	1,456,105

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Business Segment Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Business Segment Information

10. Business Segment Information

The Company conducts business as two operating segments, Transportation Services and Mobile Health services. In accordance with ASC 280, Segment Reporting, operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in two operating segments because the Company’s entities have two main revenue streams, and the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources by revenue stream.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Transportation Services and Mobile Health services segments based primarily on results of operations.

Operating results for the business segments of the Company are as follows:

	Transportation Services			Mobile Health Services		Total
Three Months Ended September 30, 2022
Revenues	$	27,670,109		$	76,649,785	$	104,319,894

Income (loss) from operations		(4,213,156	)		8,412,346	$	4,199,190

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	2,464,694		$	550,170	$	3,014,864

Stock compensation	$	373,641		$	737,562	$	1,111,203

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Three Months Ended September 30, 2021
Revenues	$	17,916,162			67,922,826	$	85,838,988

Income (loss) from operations		(11,308,739	)		12,827,957		1,519,218

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	1,860,088		$	159,488	$	2,019,576

Stock compensation	$	458,346		$	4,700	$	463,046

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

	Transportation Services			Mobile Health Services		Total
Nine Months Ended September 30, 2022
Revenues	$	77,657,852		$	254,072,898	$	331,730,750

Income (loss) from operations		(33,035,470	)		54,786,982	$	21,751,512

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	6,271,952		$	981,704	$	7,253,656

Stock compensation	$	1,253,450		$	3,280,309	$	4,533,759

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Nine Months Ended September 30, 2021
Revenues	$	65,657,142			131,737,237	$	197,394,379

Income (loss) from operations		(15,309,680	)		15,213,696		(95,984	)

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	5,214,607		$	299,696	$	5,514,303

Stock compensation	$	1,215,180		$	9,400	$	1,224,580

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

Long-lived assets include property, plant and equipment, goodwill and intangible assets.

Geographic Information

Revenues by geographic location are included in Note 2.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Equity

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Equity

11. Equity

Preferred Stock

In November 2021, the Company’s Series A preferred stock was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value $0.0001 (the “Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement. The Company’s Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity reflect the 2020 shares as if the Merger occurred in 2020.

Prior to the reverse merger, on May 23, 2019, the Series A preferred stock was formed, and 40,000 shares were authorized. Each share of Series A preferred stock was convertible into Class A common stock at a conversion price of $3,000 per share, subject to adjustment as defined in the articles of incorporation.

Series A preferred stockholders had voting rights equivalent to the number of common stock shares issuable upon conversion. The Series A preferred stockholders were entitled to a non-cumulative dividend equal to 8% of the original issue price as defined in the agreement when declared by the board of directors.

The holders of the Series A preferred stock had preferential liquidation rights and rank senior to the holders of common stock. If a liquidation were to occur, the holders of the Series A preferred stock would have been paid an amount equal to $3,000 per share, subject to adjustment as defined in the articles of incorporation, plus all accrued and unpaid dividends thereon. After the payment of the Series A preferred stockholders, the common stockholders would have been paid out on a pro-rata basis.

Common Stock

On November 1, 2017, Ambulnz, Inc. converted its legal structure from a limited liability company to a corporation and converted its membership units into shares of common stock at a rate of 1,000 shares per membership unit. The total authorized number of shares of common stock converted was 100,000 shares, comprised of 35,597 shares of Class A common stock and 64,402 shares of Class B common stock.

Prior to the reverse merger, on May 23, 2019, the Ambulnz, Inc amended and restated its articles of incorporation and the total authorized common stock increased to 154,503 shares, comprised of 78,000 shares of Class A common stock and 76,503 shares of Class B common stock. The Class A common stockholders had voting rights equivalent to one vote per share of common stock and the Class B common stockholders have no voting rights. Dividends may be paid to the common stockholders out of funds legally available, when declared by the board of directors.

Share Repurchase Program

On May 24, 2022, the Company was authorized to purchase up to $40 million of the Company’s common stock under a share repurchase program (the “Program”). During the second quarter of 2022, the Company repurchased 70,000 shares of its common stock for $498,000. These shares were subsequently cancelled. There were no shares repurchased during the third quarter of 2022. The Program does not obligate the Company to acquire any specific number of shares and will expire on November 24, 2023. Under the Program, shares may be repurchased using a variety of methods, including privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as part of accelerated share repurchases, block trades and other methods. The timing, manner, price and amount of any common stock repurchases under the Program are determined by the Company in its discretion and depend on a variety of factors, including legal requirements, price and economic and market conditions.

Preacquisition Warrants

On February 15, 2018, the Company issued warrants to purchase 1,367 shares of Class B common stock at a purchase price of $0.01 per share to an investor in conjunction with a capital investment. The warrants had no expiration date. The fair value on the date of issuance was $5,400 per share, for a total fair value of $7,381,800. On May 23, 2019, the warrants were exchanged for warrants to purchase 2,461 shares of Series A preferred stock at a purchase price of $0.01 per share. The exchanged warrants have no expiration date and had a fair value on the date of issuance of $3,000 per share for a total fair value of $7,383,000. These warrants were cashless exercised in November 2021 for 1,587,700 shares of common DocGo Inc. common stock.

On June 5, 2019, the Company issued warrants to purchase 667 shares of Series A preferred stock at a purchase price of $3,000 per share to an investor in conjunction with a capital investment. The warrants would have expired on June 6, 2029. The fair value on the date of issuance was $2,078 per warrant for a total fair value of $1,386,026. These warrants were cashless exercised in November 2021 for 229,807 shares of common DocGo Inc. common stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock Based Compensation

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock Based Compensation

12. Stock Based Compensation

Stock Options

In 2021, the Company established the DocGo Inc. Equity Incentive Plan (the “Plan”), which replaced Ambulnz, Inc’s 2017 Equity Incentive Plan. The Company reserved 16,607,894 shares of common stock for issuance under the Plan. The Company’s stock options generally vest on various terms based on continuous services over periods ranging from three to five years. The stock options are subject to time vesting requirements through 2032 and are nontransferable. Stock options granted have a maximum contractual term of 10 years. On September 30, 2022, approximately 2.5 million employee stock options on a converted basis had vested.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Before the Company’s shares of stock were publicly traded, management took the average of several publicly traded companies that were representative of the Company’s size and industry in order to estimate its expected stock volatility. The expected term of the options represented the period of time the instruments are expected to be outstanding. The Company based the risk-free interest rate on the rate payable on the U.S. Treasury securities corresponding to the expected term of the awards at the date of grant. Expected dividend yield was zero based on the fact that the Company had not historically paid and does not intend to pay a dividend in the foreseeable future.

The Company utilized contemporaneous valuations in determining the fair value of its shares at the date of option grants. Prior to the Merger, each valuation utilized both the discounted cash flow and guideline public company methodologies to estimate the fair value of its shares on a non-controlling and marketable basis. The December 31, 2020 valuations also included an approach that took into consideration a pending non-binding letter of intent from Motion Acquisition Corp. The March 11, 2021 valuation report relied solely on the fair value of the Company’s shares implied by the March 8, 2021 Merger Agreement with Motion Acquisition Corp.

A discount for lack of marketability was applied to the non-controlling and marketable fair value estimates determined above. The determination of an appropriate discount for lack of marketability was based on a review of discounts on the sale of restricted shares of publicly traded companies and put-based quantitative methods. Factors that influenced the size of the discount for lack of marketability included (a) the estimated time it would take for a Company stockholder to achieve marketability, and (b) the volatility of the Company’s business.

The following assumptions were used to compute the fair value of the stock option grants during the period ended September 30, 2022 and 2021:

	Period Ended September 30, 2022
	2022			2021
Risk-free interest rate		.07% - 2.8	%		.15% - .62	%
Expected term (in years)		4			.5 - 2
Volatility		60% - 64	%		65	%
Dividend yield		0	%		0	%

The following table summarizes the Company’s stock option activity under the Plan for the period ended September 30, 2022:

	Options Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance as of, December 31, 2021		8,422,972		$	6.21		8.77	$	24,706,020
Granted/ Vested during the year		2,183,026			5.92		9.07		-
Exercised during the year		(1,637,159	)		2.04		5.47		-
Cancelled during the year		(706,642	)		7.71		8.82		-
Balance as of September 30, 2022		8,262,197			7.04		8.72	$	22,950,815
Options vested and exercisable at September 30, 2022		2,502,717		$	6.11		8.30	$	10,010,617

The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company’s common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for stock option grants during the periods ended September 30, 2022 and December 31, 2021 was $5.92 and $2.80, respectively. On September 30, 2022 and December 31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $27,812,078 and $20,792,804, respectively, which the Company expects to recognize over a weighted-average period of approximately 3.73 years.

Restricted Stock Units

The fair value of restricted stock units (“RSUs”) is determined on the date of grant. The Company records compensation expense in the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one to four years.

Activity under RSUs was as follows:

	RSUs			Weighted- Average Grant Date Fair Value Per RSU
Balance as of, December 31, 2021		50,192		$	9.97
Granted		146,853			7.15
Vested during the year		(16,645	)		9.97
Forfeited		-			-
Balance as of, September 30, 2022		180,400			7.67
Vested and unissued at September 30, 2022		-
Non-vested at September 30, 2022		180,400			7.67

The total grant-date fair value of RSUs granted during the period ended September 30, 2022 was $1,049,999.

For the period ended September 30, 2022, the Company recorded stock-based compensation expense related to RSUs of $177,840.

As of September 30, 2022, the Company had $1,241,163 in unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted-average period of approximately 3.1 years.

Leases

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Leases

13. Leases

Operating Leases

The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space, and transportation equipment, expiring at various dates through 2026. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property. The Company is required to hold certain funds in restricted cash and cash equivalents accounts under some of these agreements.

Certain leases for property and transportation equipment contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use (ROU) asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated ROU asset and lease obligation. In making such judgment, the Company considers all relevant economic factors that would require whether to exercise or not exercise the option.

The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019, for all leases that commenced prior to that date, for office spaces and transportation equipment.

Lease Costs

The table below comprise lease expenses for the periods ended September 30, 2022 and 2021:

	Three Months Ended				Nine Months Ended
Components of total lease cost:	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021

Operating lease expense	$	626,188	$	508,128	$	1,517,541	$	1,446,067
Short-term lease expense		334,619	$	62,653		863,316		256,448
Total lease cost	$	960,807	$	570,781	$	2,380,857	$	1,702,515

Lease Position as of September 30, 2022

Right-of-use lease assets and lease liabilities for the Company’s operating leases were recorded in the Condensed Consolidated Balance Sheets as follows:

	September 30, 2022		December 31, 2021
Assets
Lease right-of-use assets	$	8,185,547	$	4,195,682
Total lease assets	$	8,185,547	$	4,195,682

Liabilities
Current liabilities:
Lease liability - current portion	$	2,059,278	$	1,461,335
Noncurrent liabilities:
Lease liability, net of current portion		6,406,246		2,980,946
Total lease liability	$	8,465,524	$	4,442,281

Lease Terms and Discount Rate

The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of September 30, 2022:

Weighted average remaining lease term (in years) - operating leases			5.22
Weighted average discount rate - operating leases			6.00	%

Undiscounted Cash Flows

Future minimum lease payments under the operating leases at September 30, 2022 are as follows:


	Operating Leases
2022, remaining	$	676,878
2023		2,375,470
2024		1,880,974
2025		1,897,247
2026		1,499,654
2027 and thereafter		1,418,692
Total future minimum lease payments		9,748,915
Less effects of discounting		(1,283,391	)
Present value of future minimum lease payments	$	8,465,524

Operating lease expense was approximately $960,807 and $570,781 for the three months ended September 30, 2022 and 2021, respectively.

Operating lease expense was approximately $2,380,857 and $1,702,515 for the nine months ended September 30, 2022 and 2021, respectively.

For the three months ended September 30, 2022, the Company made $626,188 of fixed cash payments related to operating leases and $672,975 related to finance leases.

For the three months ended September 30, 2021, the Company made $519,716 of fixed cash payments related to operating leases and $725,233 related to finance leases.

For the nine months ended September 30, 2022, the Company made $1,517,541 of fixed cash payments related to operating leases and $2,146,857 related to finance leases.

For the nine months ended September 30, 2021, the Company made $1,446,067 of fixed cash payments related to operating leases and $1,972,283 related to finance leases.

Finance Leases

The Company leases vehicles under a non-cancelable finance lease agreements with a liability of $8,945,489 and $10,139,410 as of September 30, 2022 and December 31, 2021, respectively. This includes accumulated depreciation expense of $9,662,686 and $7,095,242 as of September 30, 2022 and December 31, 2021, respectively.

Depreciation expense for the vehicles under non-cancelable lease agreements amounted to $873,713 and $752,313 for the three months ended September 30, 2022 and 2021, respectively.

Depreciation expense for the vehicles under non-cancelable lease agreements amounted to $2,391,989 and $2,109,770 for the nine months ended September 30, 2022 and 2021, respectively.

Gain on Lease Remeasurement

In June 2022, the Company reassessed its finance lease estimates relating to vehicle milage and residual value. As a result, the Company determined to purchase the vehicles at the end of the leases which resulted in a gain of $1.4 million recorded as gains from lease accounting on the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income.

Lease Payments

The table below presents lease payments for the periods ended September 30, 2022 and 2021:

	Three Months Ended				Nine Months Ended
Components of total lease payment:	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021

Finance lease payment	$	672,975	$	717,891	$	2,146,857	$	1,972,283
Short-term lease payment		-		-				-
Total lease payments	$	672,975	$	717,891	$	2,146,857	$	1,972,283

Lease Position as of September 30, 2022

Right-of-use lease assets and lease liabilities for the Company’s finance leases were recorded in the Condensed Consolidated Balance Sheets as follows:

	September 30, 2022		December 31, 2021
Assets
Lease right-of-use assets	$	9,421,196	$	9,307,113
Total lease assets	$	9,421,196	$	9,307,113

Liabilities
Current liabilities:
Lease liability - current portion	$	2,858,968	$	3,271,990
Noncurrent liabilities:
Lease liability, net of current portion		6,086,521		6,867,420
Total lease liability	$	8,945,489	$	10,139,410

Lease Terms and Discount Rate

The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of September 30, 2022:

Weighted average remaining lease term (in years) - finance leases			3.92
Weighted average discount rate - finance leases			6.01	%

Undiscounted Cash Flows

Future minimum lease payments under the finance leases at September 30, 2022 are as follows:

	Finance Leases
2022, remaining		878,626
2023		3,127,590
2024		2,398,030
2025		2,095,826
2026		1,185,433
2027 and thereafter		274,974
Total future minimum lease payments		9,960,479
Less effects of discounting		(1,014,990	)
Present value of future minimum lease payments	$	8,945,489

Future minimum lease payments under the operating leases at September 30, 2022 are as follows:

	Operating Leases
2022, remaining	$	676,878
2023		2,375,470
2024		1,880,974
2025		1,897,247
2026		1,499,654
2027 and thereafter		1,418,692
Total future minimum lease payments		9,748,915
Less effects of discounting		(1,283,391	)
Present value of future minimum lease payments	$	8,465,524

Other Expense

9 Months Ended

Sep. 30, 2022

Other Income and Expenses [Abstract]

Other Expense

14. Other Expense

As of September 30, 2022, the Company recorded a loss of approximately $1.8 million from the remeasurement of warrant liabilities. The warrants are marked-to-market in each reporting period, and this loss reflected the increase in DocGo’s stock price relative to the beginning of the period. No gain or loss was recorded in relation to the remeasurement of warrant liabilities in the same period in 2021. The Company redeemed all of its outstanding warrants in September 2022.

Related Party Transactions

9 Months Ended

Sep. 30, 2022

Related Party Transactions

15. Related Party Transactions

Historically, the Company has been involved in transactions with various related parties.

Ely D. Tendler Strategic & Legal Services PLLC provides legal services for the Company. Ely D. Tendler Strategic & Legal Services PLLC is owned by the General Counsel of the Company, and therefore is a related party. The Company made legal payments to Ely D. Tendler Strategic & Legal Services PLLC totaling $261,185 and $186,075 for the three months ended September 30, 2022 and 2021, respectively, and $704,593 and $476,293 for the nine months ended September 30, 2022 and 2021, respectively.

Pride Staff also provides subcontractor services for the Company. The Pride Staff is owned by the operations manager of the Company and his spouse, and therefore, a related party. The Company made subcontractor payments to PrideStaff totaling $118,645 and $92,359 for the three months ended September 30, 2022 and 2021, respectively, and $364,844 and $592,417 for the nine months ended September 30, 2022 and 2021, respectively.

Included in accounts payable were $118,604 and $94,636 due to related parties as of September 30, 2022 and December 31, 2021, respectively.

Income Taxes

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

16. Income Taxes

As a result of the Company’s history of net operating losses (“NOL”), the Company had historically provided for a full valuation allowance against its deferred tax assets for assets that were not more-likely-than-not to be realized. The Company’s income expense for the three months ended September 30, 2022 and 2021 were $401,906 and $604,608, respectively, and $1,163,755 and $613,531 for the nine months ended September 30, 2022 and 2021, respectively. In determining the quarterly provision for income taxes, we use an estimated annual effective tax rate adjusted for discrete items. This rate is based on our expected annual income, statutory tax rates, and best estimates of non-taxable and non-deductible income and expense items.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

401(K) Plan

9 Months Ended

Sep. 30, 2022

Retirement Benefits [Abstract]

401(K) Plan

17. 401(K) Plan

The Company has established a 401(k) plan in January 2022 that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. All U.S. employees that complete two months of service with the Company are eligible to participate in the plan. The Company did not make any employer contributions to this plan as of September 30, 2022.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Legal Proceedings

9 Months Ended

Sep. 30, 2022

Legal Proceedings [Abstract]

Legal Proceedings

18. Legal Proceedings

From time to time, the Company may be involved as a defendant in legal actions that arise in the normal course of business. In the opinion of management, the Company has adequate legal defense on all legal actions, and the results of any such proceedings would not materially impact the Unaudited Condensed Consolidated Financial Statements of the Company. The Company provides disclosure and records loss contingencies in accordance with the loss contingencies accounting guidance. In accordance with such guidance, the Company establishes accruals for such matters when potential losses become probable and can be reasonably estimated. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss in the Unaudited Condensed Consolidated Financial Statements.

As of September 30, 2022 and December 31, 2021, the Company recorded a liability of $1,000,000, which represents an amount for an agreed settlement, under the terms of a memorandum of understanding, of various class-based claims, both actual and potential, under Federal and California state law, as described in detail below. The settlement is subject to court approval.

Stephanie Zamora, Jascha Dlugatch, et al. v. Ambulnz Health, LLC, et al. was filed in the Los Angeles Superior Court on October 11, 2018, and the complaint alleged wage and hour violations pursuant to California’s Private Attorneys’ General Act of 2004 (“PAGA”). On February 24, 2020, this case was consolidated with Jascha Dlugatch, et. Al. v. Ambulnz Health, LLC (the “Consolidated Compliant”), another lawsuit filed in the Los Angeles Superior Court. On May 6, 2021, the parties attended mediation and settled the claims pled in the Consolidated Complaint on a class-wide and PAGA basis in exchange for a proposed $1 million payment by Ambulnz Health, inclusive of administrative costs and fees. On September 9, 2022, the Court preliminarily approved the proposed settlement.

Risk and Uncertainties

9 Months Ended

Sep. 30, 2022

Risks and Uncertainties [Abstract]

Risk and Uncertainties

19. Risk and Uncertainties

COVID-19 Risks, Impacts and Uncertainties

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 Outbreak”) and the risks to the international community as the virus spreads globally. In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally.

The spread of COVID-19 and the related country-wide shutdowns and restrictions had a mixed impact on the Company’s business. In the ambulance transportation business, which predominantly comprises of non-emergency medical transportation, the Company saw a decline in volumes from historical and expected levels, as elective surgeries and other procedures were postponed. In some of the Company’s larger markets, such as New York and California, there were declines in trip volume. In addition, the Company experienced lost revenues associated with sporting, concerts and other events, as those events were cancelled or had a significantly restricted (or entirely eliminated) the number of permitted attendees. Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There are two areas where the Company has experienced positive business impacts from COVID-19. In April and May 2020, the Company participated in an emergency project with Federal Emergency Management Agency (“FEMA”) in the New York City area. This engagement resulted in incremental transportation revenue. In addition, in response to the need for widespread COVID-19 testing and available Emergency Medical Technicians (“EMT”) and Paramedics, the Company formed a new subsidiary, Rapid Reliable Testing, LLC (“RRT”), with the goal to perform COVID-19 tests at nursing homes, municipal sites, businesses, schools and other venues. RRT is part of the Mobile Health segment. Since early 2020, RRT has grown significantly, and its services have expanded beyond COVID-19 testing to a wide variety of tests, vaccinations and other procedures. While COVID-19 testing activity continued to grow throughout 2021 and into early 2022, such activity has slowed considerably over the past several months, as the pandemic has waned, and COVID-19 testing accounted for a relatively small proportion of the Company’s overall revenues during the third quarter of 2022. We anticipate that COVID-19 will continue to account for a shrinking proportion of the Company’s revenues in the fourth quarter of 2022 and beyond.

The Company’s current business plan assumes continued recovery of industry-wide transportation volumes to historical levels and beyond, plus an increased demand for mobile health services, a demand that was accelerated by the pandemic, but which is also being driven by longer-term secular factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s offices and hospitals. However, given the unpredictable, unprecedented, and fluid nature of the pandemic and its economic consequences, we are unable to predict the duration and extent to which the pandemic and its related positive and negative impacts will affect our business, financial condition, and results of operations in future periods. Likewise, we are unable to predict the emergence of future, unrelated pandemics, which would have some of the same impacts as those experienced with COVID-19.

Medicare Accelerated Payments

Medicare accelerated payments of approximately $2,397,024 were received by the Company in April 2020. Effective October 8, 2020, CMS is no longer accepting new applications for accelerated payments. Accordingly, the Company does not expect to receive additional Medicare accelerated payments. Payments under the Medicare Accelerated and Advance Payment program are advances that must be repaid. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. There were no Medicare accelerated payments reflected within accrued liabilities in the Condensed Consolidated Balance Sheets as of September 30, 2022, compared to $975,415 as of December 31, 2021. The Company’s estimate of the current liability is a function of historical cash receipts from Medicare and the repayment terms set forth above.

Subsequent Events

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Subsequent Events

20. Subsequent Events

On October 12, 2022, the Company acquired Community Ambulance Service Ltd, a company located in United Kingdom, in exchange for approximately £4.8 million in cash. Community Ambulance Service Ltd is engaged in providing emergency and non-emergency transport services, including high dependency, urgent care, mental health and blue light transport services and diagnostics testing. We believe this acquisition will allow us to increase our presence in that market, while giving us improved access to municipal contracts. We are currently in the process of finalizing the accounting for this transaction and will have completed our preliminary allocation of the purchase consideration to the asset acquired and liabilities assumed as of the end of the fourth quarter of 2022.

On November 1, 2022, the Company entered into a revolving loan and security agreement with two banks, with one bank as the administrative agent (the “Lenders”), with a maximum revolving advance amount of $90,000,000. The revolving facility includes the ability for the Company to request an increase to the commitment by an additional up to $50,000,000, though no Lender (nor the Lenders collectively) are obligated to increase their respective commitments. Borrowings under the revolving facility bear interest at a per annum rate equal to, (i) at the Company’s option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins are 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and will be updated based on the consolidated net leverage ratio reported in the compliance certificate. The revolving facility matures on the five-year anniversary of the closing date, November 1, 2027. The revolving facility is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets. The revolving facility is subject to certain financial covenants such as a net leverage ratio and interest coverage ratio, as defined in the agreement. The Company has not made any draws under the facility and there is no amount outstanding.

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

Foreign Currency

Foreign Currency

Use of Estimates

Use of Estimates

Concentration of Credit Risk and Off-Balance Sheet Risk

Concentration of Credit Risk and Off-Balance Sheet Risk

Major Customers

Major Customers

Emerging Growth Company

Emerging Growth Company

Cash and Cash Equivalents

Cash and Cash Equivalents

Restricted Cash and Insurance Reserves

Restricted Cash and Insurance Reserves

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Accounts Receivable

Accounts Receivable

Property and Equipment

Property and Equipment

Asset Category		Estimated Useful Life
Buildings		39 years
Office equipment and furniture		3 years
Vehicles		2-8 years
Medical equipment		2-5 years
Leasehold improvements		Shorter of useful life of asset or lease term

Expenditures for repairs and maintenance are expensed as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.

Software Development Costs

Software Development Costs

Business Combinations

Business Combinations

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Goodwill and Indefinite-Lived Intangible Assets

Line of Credit

Line of Credit

The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense.

Derivative Financial Instruments

Derivative Financial Instruments

Related Party Transactions

Related Party Transactions

Revenue Recognition

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”), as amended.

Nature of Our Services

Revenue is primarily derived from:

ii.

In the following table, revenue is disaggregated as follows:

Revenue Breakdown Three Months Ended
September 30, Nine Months Ended
September 30, 2022 2021 2022 2021 Primary Geographical Markets United States $101,337,899 $83,286,509 $322,706,143 $190,595,217 United Kingdom 2,981,995 2,552,479 9,024,607 6,799,162 Total revenue $104,319,894 $85,838,988 $331,730,750 $197,394,379 Major Segments/Service Lines Transportation Services $27,670,109 $17,916,162 $77,657,852 $65,657,141 Mobile Health 76,649,785 67,922,826 254,072,898 131,737,238 Total revenue $104,319,894 $85,838,988 $331,730,750 $197,394,379

Stock Based Compensation

Stock Based Compensation

Earnings per Share

Earnings per Share

Equity Method Investment

Equity Method Investment

Leases

Leases

Income Taxes

Income Taxes

Recently Issued Accounting Standards Not Yet Adopted

Recently Issued Accounting Standards Not Yet Adopted

None

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets

Asset Category		Estimated Useful Life
Buildings		39 years
Office equipment and furniture		3 years
Vehicles		2-8 years
Medical equipment		2-5 years
Leasehold improvements		Shorter of useful life of asset or lease term

Schedule of revenue is disaggregated

Revenue Breakdown	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Primary Geographical Markets
United States	$	101,337,899	$	83,286,509	$	322,706,143	$	190,595,217
United Kingdom		2,981,995		2,552,479		9,024,607		6,799,162
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Major Segments/Service Lines
Transportation Services	$	27,670,109	$	17,916,162	$	77,657,852	$	65,657,141
Mobile Health		76,649,785		67,922,826		254,072,898		131,737,238
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

Schedule of property and equipment, net

	September 30, 2022			December 31, 2021

Office equipment and furniture	$	2,749,874		$	1,977,808
Buildings		527,283			527,284
Land		37,800			37,800
Transportation equipment		18,477,444			13,772,251
Medical equipment		5,764,863			3,949,566
Leasehold improvements		609,226			616,446
		28,166,490			20,881,155
Less: Accumulated depreciation		(10,588,660	)		(8,147,266	)
Property and equipment, net	$	17,577,830		$	12,733,889

Acquisition of Businesses (Tables)

9 Months Ended

Sep. 30, 2022

Acquisition of Businesses and Asset Acquisitions [Abstract]

Schedule of allocated based on the purchase price

	Ryan Brothers		Exceptional Medical Transport		GMS		Total

Consideration:
Cash Consideration	$	7,422,252	$	6,375,000	$	20,338,789	$	34,136,041
Due to Seller		-		6,000,000		-		6,000,000
Contingent Consideration		4,000,000		-		-		4,000,000
Amounts held under an escrow account		-		1,333,333		-		1,333,333
Total consideration		11,422,252		13,708,333		20,338,789		45,469,374

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	620,548	$	299,050	$	1,005,453	$	1,925,051
Accounts receivable		-		-		3,975,160		3,975,160
Other current assets		136,157		-		30,734		166,891
Property, plant and equipment		2,125,134		2,450,900		4,092		4,580,126
Intangible assets		387,550		125,000		9,794,000		10,306,550
Total identifiable assets acquired		3,269,389		2,874,950		14,809,439		20,953,778

Accounts payable		44,911		-		137,239		182,150
Due to Seller		-		299,050		-		299,050
Other current liabilities		286,792		-		562,809		849,601
Total liabilities assumed		331,703		299,050		700,048		1,330,801

Goodwill		8,484,566		11,132,433		6,229,398		25,846,397

Total purchase price	$	11,422,252	$	13,708,333	$	20,338,789	$	45,469,374

Goodwill (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill [Abstract]

Schedule of changes in the carrying value of goodwill

	Carrying Value
Balance at December 31, 2021	$	8,686,966
Goodwill acquired during the period		25,846,397
Balance at September 30, 2022		34,533,363

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Intangibles (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of amortization expense

	September 30, 2022
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	48,668	$	13,655	$	(9,075	)	$	53,248
Computer software	5 years	$	294,147		11,144		(263,192	)	$	42,099
Operating licenses	Indefinite	$	8,375,514		450,200		-		$	8,825,714
Internally developed software	4-5 years	$	6,013,513		1,907,616		(5,778,894	)	$	2,142,235
Material Contracts	Indefinite		-		62,550		-			62,550
Customer Relationship	9 years		-		9,794,000		(272,056	)	$	9,521,944
		$	14,731,842	$	12,239,165	$	(6,323,217	)	$	20,647,790

	December 31, 2021
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	19,275	$	29,393	$	(6,367	)	$	42,301
Computer software	5 years		132,816		161,331		(219,388	)		74,759
Operating licenses	Indefinite		8,375,514		-		-			8,375,514
Internally developed software	4-5 years		2,146,501		3,867,012		(3,828,038	)		2,185,475
		$	10,674,106	$	4,057,736	$	(4,053,793	)	$	10,678,049

Schedule of amortization expense for the next five years in aggregate

	Amortization Expense
2022, remaining	$	680,930
2023		2,078,406
2024		1,510,563
2025		1,460,965
2026		1,094,588
Thereafter		4,934,074
Total	$	11,759,526

Amortization expense
As of September 30, 2022			2,269,423
As of September 30, 2021			1,432,983
As of December 31, 2021			1,845,193

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Accrued Liabilities [Abstract]

Schedule of accrued liabilities

	September 30, 2022		December 31, 2021
Accrued bonus	$	496,660	$	7,260,456
Accrued lab fees		1,363,138		4,885,539
Accrued payroll		7,068,616		3,539,301
Medicare advance		-		975,415
FICA/Medicare liability		759,232		739,629
Accrued general expenses		7,393,906		3,497,418
Accrued subcontractors		11,259,341		9,564,833
Accrued fuel and maintenance		310,064		450,842
Accrued workers compensation		5,465,030		2,259,571
Other current liabilities		12,259		736,021
Accrued legal fees		2,447,997		1,143,629
Accrued insurance liabilities		1,840,420		-
Credit card payable		141,411		58,223
Total accrued liabilities	$	38,558,074	$	35,110,877

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2022

Notes Payable [Abstract]

Schedule of notes payable

	September 30, 2022		December 31, 2021
Equipment and financing loans payable, between 2.5% and 8% interest and maturing between January 2022 and May 2051	$	2,136,808	$	1,903,288
Loan received pursuant to the Payroll Protection Program Term Note		-		-
Total notes payable		2,136,808		1,903,288
Less: current portion of notes payable	$	680,703	$	600,449
Total non-current portion of notes payable	$	1,456,105	$	1,302,839

Schedule of future minimum annual maturites of notes payable

	Notes Payable
2022, remaining		137,959
2023		582,722
2024		446,812
2025		386,785
2026		311,769
Thereafter		270,761
Total maturities	$	2,136,808
Current portion of notes payable		(680,703	)
Long-term portion of notes payable	$	1,456,105

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Business Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of operating results for the business segments

	Transportation Services			Mobile Health Services		Total
Three Months Ended September 30, 2022
Revenues	$	27,670,109		$	76,649,785	$	104,319,894

Income (loss) from operations		(4,213,156	)		8,412,346	$	4,199,190

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	2,464,694		$	550,170	$	3,014,864

Stock compensation	$	373,641		$	737,562	$	1,111,203

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Three Months Ended September 30, 2021
Revenues	$	17,916,162			67,922,826	$	85,838,988

Income (loss) from operations		(11,308,739	)		12,827,957		1,519,218

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	1,860,088		$	159,488	$	2,019,576

Stock compensation	$	458,346		$	4,700	$	463,046

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

	Transportation Services			Mobile Health Services		Total
Nine Months Ended September 30, 2022
Revenues	$	77,657,852		$	254,072,898	$	331,730,750

Income (loss) from operations		(33,035,470	)		54,786,982	$	21,751,512

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	6,271,952		$	981,704	$	7,253,656

Stock compensation	$	1,253,450		$	3,280,309	$	4,533,759

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Nine Months Ended September 30, 2021
Revenues	$	65,657,142			131,737,237	$	197,394,379

Income (loss) from operations		(15,309,680	)		15,213,696		(95,984	)

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	5,214,607		$	299,696	$	5,514,303

Stock compensation	$	1,215,180		$	9,400	$	1,224,580

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of fair value of the sole stock option grants

	Period Ended September 30, 2022
	2022			2021
Risk-free interest rate		.07% - 2.8	%		.15% - .62	%
Expected term (in years)		4			.5 - 2
Volatility		60% - 64	%		65	%
Dividend yield		0	%		0	%

Schedule of company’s stock option activity

	Options Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance as of, December 31, 2021		8,422,972		$	6.21		8.77	$	24,706,020
Granted/ Vested during the year		2,183,026			5.92		9.07		-
Exercised during the year		(1,637,159	)		2.04		5.47		-
Cancelled during the year		(706,642	)		7.71		8.82		-
Balance as of September 30, 2022		8,262,197			7.04		8.72	$	22,950,815
Options vested and exercisable at September 30, 2022		2,502,717		$	6.11		8.30	$	10,010,617

Schedule of activity under RSUs

	RSUs			Weighted- Average Grant Date Fair Value Per RSU
Balance as of, December 31, 2021		50,192		$	9.97
Granted		146,853			7.15
Vested during the year		(16,645	)		9.97
Forfeited		-			-
Balance as of, September 30, 2022		180,400			7.67
Vested and unissued at September 30, 2022		-
Non-vested at September 30, 2022		180,400			7.67

Leases (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of comprise lease expenses

	Three Months Ended				Nine Months Ended
Components of total lease cost:	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021

Operating lease expense	$	626,188	$	508,128	$	1,517,541	$	1,446,067
Short-term lease expense		334,619	$	62,653		863,316		256,448
Total lease cost	$	960,807	$	570,781	$	2,380,857	$	1,702,515

	Three Months Ended				Nine Months Ended
Components of total lease payment:	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021

Finance lease payment	$	672,975	$	717,891	$	2,146,857	$	1,972,283
Short-term lease payment		-		-				-
Total lease payments	$	672,975	$	717,891	$	2,146,857	$	1,972,283

Schedule of company’s operating leases were recorded in the condensed consolidated balance sheets

	September 30, 2022		December 31, 2021
Assets
Lease right-of-use assets	$	8,185,547	$	4,195,682
Total lease assets	$	8,185,547	$	4,195,682

Liabilities
Current liabilities:
Lease liability - current portion	$	2,059,278	$	1,461,335
Noncurrent liabilities:
Lease liability, net of current portion		6,406,246		2,980,946
Total lease liability	$	8,465,524	$	4,442,281

	September 30, 2022		December 31, 2021
Assets
Lease right-of-use assets	$	9,421,196	$	9,307,113
Total lease assets	$	9,421,196	$	9,307,113

Liabilities
Current liabilities:
Lease liability - current portion	$	2,858,968	$	3,271,990
Noncurrent liabilities:
Lease liability, net of current portion		6,086,521		6,867,420
Total lease liability	$	8,945,489	$	10,139,410

Schedule of weighted average remaining lease term and the weighted average discount rate

Weighted average remaining lease term (in years) - operating leases			5.22
Weighted average discount rate - operating leases			6.00	%

Weighted average remaining lease term (in years) - finance leases			3.92
Weighted average discount rate - finance leases			6.01	%

Schedule of future minimum lease payments under the operating leases


	Operating Leases
2022, remaining	$	676,878
2023		2,375,470
2024		1,880,974
2025		1,897,247
2026		1,499,654
2027 and thereafter		1,418,692
Total future minimum lease payments		9,748,915
Less effects of discounting		(1,283,391	)
Present value of future minimum lease payments	$	8,465,524

	Finance Leases
2022, remaining		878,626
2023		3,127,590
2024		2,398,030
2025		2,095,826
2026		1,185,433
2027 and thereafter		274,974
Total future minimum lease payments		9,960,479
Less effects of discounting		(1,014,990	)
Present value of future minimum lease payments	$	8,945,489

	Operating Leases
2022, remaining	$	676,878
2023		2,375,470
2024		1,880,974
2025		1,897,247
2026		1,499,654
2027 and thereafter		1,418,692
Total future minimum lease payments		9,748,915
Less effects of discounting		(1,283,391	)
Present value of future minimum lease payments	$	8,465,524

Description of Organization and Business Operations (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2022	Nov. 30, 2021
Description of Organization and Business Operations (Details) [Line Items]
Net proceeds	$ 158.0
Cash held in trust account	43.4
Transaction costs	$ 9.6
Common Stock [Member]
Description of Organization and Business Operations (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Summary of Significant Accounting Policies (Details)	1 Months Ended	3 Months Ended	9 Months Ended
Summary of Significant Accounting Policies (Details)	Oct. 26, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Summary of Significant Accounting Policies (Details) [Line Items]
Net Loss				$ 321,079
Total assets				220,081
Total Stockholders deficit				$ 30,914
Number of customers			1	1
Cash balances		$ 433,000	$ 433,000		$ 913,000
LLC Business Acquisition [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration		$ 4,000,000
Customer One [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage			33.00%	44.00%
Customer [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage			0.1%
RND Health Services Inc. [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Percentage of acquired Interest	50.00%
Acquired amount	$ 655,876
Business Combination [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Voting interest		10.00%	10.00%
Variable Interest Entity [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Net Loss			$ 207,368
Total assets		$ 301,503	301,503
Total liabilities		933,977	933,977
Total Stockholders deficit		$ 632,474	$ 632,474
Sales [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage			35.00%	42.00%
Sales [Member] \| Customer [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk, percentage			11.00%

Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets	9 Months Ended
	Sep. 30, 2022
Buildings [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	39 years
Office equipment and furniture [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	3 years
Vehicles [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	2 years
Vehicles [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	8 years
Medical equipment [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	2 years
Medical equipment [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	5 years
Leasehold improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Property, Plant and Equipment	Shorter of useful life of asset or lease term

Summary of Significant Accounting Policies (Details) - Schedule of revenue is disaggregated - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Primary Geographical Markets [Member]
Primary Geographical Markets
Total revenue	$ 104,319,894	$ 85,838,988	$ 331,730,750	$ 197,394,379
Major Segments/Service Lines [Member]
Primary Geographical Markets
Total revenue	104,319,894	85,838,988	331,730,750	197,394,379
Transportation Services [Member] \| Major Segments/Service Lines [Member]
Primary Geographical Markets
Total revenue	27,670,109	17,916,162	77,657,852	65,657,141
Mobile Health [Member] \| Major Segments/Service Lines [Member]
Primary Geographical Markets
Total revenue	76,649,785	67,922,826	254,072,898	131,737,238
UNITED STATES \| Primary Geographical Markets [Member]
Primary Geographical Markets
Total revenue	101,337,899	83,286,509	322,706,143	190,595,217
UNITED KINGDOM \| Primary Geographical Markets [Member]
Primary Geographical Markets
Total revenue	$ 2,981,995	$ 2,552,479	$ 9,024,607	$ 6,799,162

Property and Equipment, net (Details) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment, net (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,150,806	$ 598,188	$ 2,592,244	$ 1,697,380

Property and Equipment, net (Details) - Schedule of property and equipment, net - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment	$ 28,166,490	$ 20,881,155
Less: Accumulated depreciation	(10,588,660)	(8,147,266)
Property and equipment, net	17,577,830	12,733,889
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,749,874	1,977,808
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	527,283	527,284
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	37,800	37,800
Transportation equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	18,477,444	13,772,251
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	5,764,863	3,949,566
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 609,226	$ 616,446

Acquisition of Businesses (Details) - USD ($)				3 Months Ended	9 Months Ended
Acquisition of Businesses (Details) - USD ($)	Aug. 09, 2022	Jul. 13, 2022	Jul. 06, 2022	Sep. 30, 2022	Sep. 30, 2022
Government Medical Services, LLC Acquisition [Member]
Acquisition of Businesses (Details) [Line Items]
Acquired outstanding percentage			100.00%
Acquired exchange in cash			$ 20,300,000
Seller additional amount			$ 3,000,000
General and administrative expenses				$ 0	$ 800,000
Exceptional Medical Transportation, LLC Acquisition [Member]
Acquisition of Businesses (Details) [Line Items]
Acquired outstanding percentage		100.00%
General and administrative expenses				0	0
Exchange consisting		$ 13,700,000
Cash consideration		7,700,000
Acquisition of businesses other payable		$ 6,000,000
Ryan Brothers. Fort Atkinson, LLC Acquisition [Member]
Acquisition of Businesses (Details) [Line Items]
Acquired outstanding percentage	100.00%
General and administrative expenses				$ 0	$ 0
Exchange consisting	$ 11,400,000
Cash consideration	7,400,000
Acquisition of businesses other payable	$ 4,000,000

Acquisition of Businesses (Details) - Schedule of allocated based on the purchase price	9 Months Ended
	Sep. 30, 2022 USD ($)
Consideration:
Cash Consideration	$ 34,136,041
Due to Seller	6,000,000
Contingent Consideration	4,000,000
Amounts held under an escrow account	1,333,333
Total consideration	45,469,374
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	1,925,051
Accounts receivable	3,975,160
Other current assets	166,891
Property, plant and equipment	4,580,126
Intangible assets	10,306,550
Total identifiable assets acquired	20,953,778
Accounts payable	182,150
Due to Seller	299,050
Other current liabilities	849,601
Total liabilities assumed	1,330,801
Goodwill	25,846,397
Total purchase price	45,469,374
Ryan Brothers [Member]
Consideration:
Cash Consideration	7,422,252
Due to Seller
Contingent Consideration	4,000,000
Amounts held under an escrow account
Total consideration	11,422,252
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	620,548
Accounts receivable
Other current assets	136,157
Property, plant and equipment	2,125,134
Intangible assets	387,550
Total identifiable assets acquired	3,269,389
Accounts payable	44,911
Due to Seller
Other current liabilities	286,792
Total liabilities assumed	331,703
Goodwill	8,484,566
Total purchase price	11,422,252
Exceptional Medical Transport [Member]
Consideration:
Cash Consideration	6,375,000
Due to Seller	6,000,000
Contingent Consideration
Amounts held under an escrow account	1,333,333
Total consideration	13,708,333
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	299,050
Accounts receivable
Other current assets
Property, plant and equipment	2,450,900
Intangible assets	125,000
Total identifiable assets acquired	2,874,950
Accounts payable
Due to Seller	299,050
Other current liabilities
Total liabilities assumed	299,050
Goodwill	11,132,433
Total purchase price	13,708,333
GMS [Member]
Consideration:
Cash Consideration	20,338,789
Due to Seller
Contingent Consideration
Amounts held under an escrow account
Total consideration	20,338,789
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	1,005,453
Accounts receivable	3,975,160
Other current assets	30,734
Property, plant and equipment	4,092
Intangible assets	9,794,000
Total identifiable assets acquired	14,809,439
Accounts payable	137,239
Due to Seller
Other current liabilities	562,809
Total liabilities assumed	700,048
Goodwill	6,229,398
Total purchase price	$ 20,338,789

Goodwill (Details) - Schedule of changes in the carrying value of goodwill	9 Months Ended
	Sep. 30, 2022 USD ($)
Schedule Of Changes In The Carrying Value Of Goodwill Abstract
Balance at beginning	$ 8,686,966
Goodwill acquired during the period	25,846,397
Balance at ending	$ 34,533,363

Intangibles (Details) - USD ($)	3 Months Ended		9 Months Ended
Intangibles (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 990,345	$ 552,999	$ 2,269,423	$ 1,432,983
Amortization expense term			5 years

Intangibles (Details) - Schedule of amortization expense - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 14,731,842	$ 10,674,106
Additions	12,239,165	4,057,736
Accumulated Amortization	(6,323,217)	(4,053,793)
Net Carrying Amount	20,647,790	10,678,049
Accumulated Amortization	$ (28,166,490)	$ (20,881,155)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	15 years	15 years
Gross Carrying Amount	$ 48,668	$ 19,275
Additions	13,655	29,393
Accumulated Amortization	(9,075)	(6,367)
Net Carrying Amount	$ 53,248	$ 42,301
Computer software [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Gross Carrying Amount	$ 294,147	$ 132,816
Additions	11,144	161,331
Accumulated Amortization	(263,192)	(219,388)
Net Carrying Amount	$ 42,099	$ 74,759
Operating licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	Indefinite	Indefinite
Gross Carrying Amount	$ 8,375,514	$ 8,375,514
Additions	450,200
Accumulated Amortization
Net Carrying Amount	8,825,714	8,375,514
Internally developed software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,013,513	2,146,501
Additions	1,907,616	3,867,012
Accumulated Amortization	(5,778,894)	(3,828,038)
Net Carrying Amount	$ 2,142,235	$ 2,185,475
Internally developed software [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	4 years	4 years
Internally developed software [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Material Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	Indefinite
Additions	$ 62,550
Net Carrying Amount	$ 62,550
Customer Relationship [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	9 years
Additions	$ 9,794,000
Accumulated Amortization	(272,056)
Net Carrying Amount	$ 9,521,944

Intangibles (Details) - Schedule of amortization expense for the next five years in aggregate - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Schedule Of Amortization Expense For The Next Five Years In Aggregate Abstract
2022, remaining	$ 680,930
2023	2,078,406
2024	1,510,563
2025	1,460,965
2026	1,094,588
Thereafter	4,934,074
Total	11,759,526
Amortization expense	$ 2,269,423	$ 1,845,193	$ 1,432,983

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Accrued Liabilities Abstract
Accrued bonus	$ 496,660	$ 7,260,456
Accrued lab fees	1,363,138	4,885,539
Accrued payroll	7,068,616	3,539,301
Medicare advance		975,415
FICA/Medicare liability	759,232	739,629
Accrued general expenses	7,393,906	3,497,418
Accrued subcontractors	11,259,341	9,564,833
Accrued fuel and maintenance	310,064	450,842
Accrued workers compensation	5,465,030	2,259,571
Other current liabilities	12,259	736,021
Accrued legal fees	2,447,997	1,143,629
Accrued insurance liabilities	1,840,420
Credit card payable	141,411	58,223
Total accrued liabilities	$ 38,558,074	$ 35,110,877

Line of Credit (Details) - USD ($)	1 Months Ended		9 Months Ended
Line of Credit (Details) - USD ($)	Jan. 26, 2022	Dec. 17, 2021	Sep. 30, 2022
Line of Credit (Details) [Line Items]
Revolving advance amount		$ 12,000,000
Each revolving advances description		Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (6.25% at September 30, 2022), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period.
Unused fee		0.50%
Fund operations	$ 1,000,000
Outstanding balance			$ 1,000,000
Revolving commitment amount		$ 12
DocGo Inc [Member]
Line of Credit (Details) [Line Items]
Loan secured by assets		100.00%

Notes Payable (Details) - USD ($)	9 Months Ended	12 Months Ended
Notes Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Notes Payable (Details) [Line Items]
Aggregate installment amount	$ 64,855
Interest expense	$ 69,804	$ 61,324
Minimum [Member]
Notes Payable (Details) [Line Items]
Interest range percentage	2.50%	2.50%
Maximum [Member]
Notes Payable (Details) [Line Items]
Interest range percentage	8.00%	8.00%

Notes Payable (Details) - Schedule of notes payable - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Notes Payable Abstract
Equipment and financing loans payable, between 2.5% and 8% interest and maturing between January 2022 and May 2051	$ 2,136,808	$ 1,903,288
Loan received pursuant to the Payroll Protection Program Term Note
Total notes payable	2,136,808	1,903,288
Less: current portion of notes payable	680,703	600,449
Total non-current portion of notes payable	$ 1,456,105	$ 1,302,839

Notes Payable (Details) - Schedule of notes payable (Parentheticals)	Sep. 30, 2022	Dec. 31, 2021
Minimum [Member]
Notes Payable (Details) - Schedule of notes payable (Parentheticals) [Line Items]
Equipment and financing loans payable	2.50%	2.50%
Maximum [Member]
Notes Payable (Details) - Schedule of notes payable (Parentheticals) [Line Items]
Equipment and financing loans payable	8.00%	8.00%

Notes Payable (Details) - Schedule of future minimum annual maturities of notes payable	Sep. 30, 2022 USD ($)
Schedule Of Future Minimum Annual Maturities Of Notes Payable Abstract
2022, remaining	$ 137,959
2023	582,722
2024	446,812
2025	386,785
2026	311,769
Thereafter	270,761
Total maturities	2,136,808
Current portion of notes payable	(680,703)
Long-term portion of notes payable	$ 1,456,105

Business Segment Information (Details) - Schedule of operating results for the business segments - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenues	$ 104,319,894	$ 85,838,988	$ 331,730,750	$ 197,394,379
Income (loss) from operations	4,199,190	1,519,218	21,751,512	(95,984)
Total assets	355,920,210	144,078,865	355,920,210	144,078,865
Depreciation and amortization expense	3,014,864	2,019,576	7,253,656	5,514,303
Stock compensation	1,111,203	463,046	4,533,759	1,224,580
Long-lived assets	72,758,983	27,894,236	72,758,983	27,894,236
Transportation Services [Member]
Segment Reporting Information [Line Items]
Revenues	27,670,109	17,916,162	77,657,852	65,657,142
Income (loss) from operations	(4,213,156)	(11,308,739)	(33,035,470)	(15,309,680)
Total assets	173,789,449	115,444,782	173,789,449	115,444,782
Depreciation and amortization expense	2,464,694	1,860,088	6,271,952	5,214,607
Stock compensation	373,641	458,346	1,253,450	1,215,180
Long-lived assets	19,584,744	25,641,586	19,584,744	25,641,586
Mobile Health Services [Member]
Segment Reporting Information [Line Items]
Revenues	76,649,785	67,922,826	254,072,898	131,737,237
Income (loss) from operations	8,412,346	12,827,957	54,786,982	15,213,696
Total assets	182,130,761	28,634,083	182,130,761	28,634,083
Depreciation and amortization expense	550,170	159,488	981,704	299,696
Stock compensation	737,562	4,700	3,280,309	9,400
Long-lived assets	$ 53,174,239	$ 2,252,650	$ 53,174,239	$ 2,252,650

- Definition

Amount after tax of income (loss) from continuing operations attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

+ Details

Equity (Details) - USD ($)			1 Months Ended			9 Months Ended
Equity (Details) - USD ($)	Jun. 05, 2019	Nov. 01, 2017	Nov. 30, 2021	May 23, 2019	Feb. 15, 2018	Sep. 30, 2022	Jun. 30, 2022	May 24, 2022
Equity (Details) [Line Items]
Common stock repurchased amount (in Dollars)							$ 498,000	$ 40,000,000
Common stock repurchased share							70,000
Expired date	Jun. 06, 2029
Common Stock [Member]
Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)			$ 0.0001			$ 0.0001
Number of common stock rate		1,000
Common stock converted		100,000
Total authorized common shares increased				154,503
Common stock voting rights, description						The Class A common stockholders had voting rights equivalent to one vote per share of common stock and the Class B common stockholders have no voting rights.
Warrant [Member]
Equity (Details) [Line Items]
Number of warrant to purchase shares	667
Purchase price (in Dollars per share)	$ 3,000
Issuance of fair value (in Dollars per share)	$ 2,078			$ 3,000	$ 5,400
Total fair value (in Dollars)	$ 1,386,026			$ 7,383,000	$ 7,381,800
Warrant cashless exercised	229,807		1,587,700
Series A Preferred Stock [Member]
Equity (Details) [Line Items]
Preferred stock share authorized				40,000
Percentage non-cumulative dividends						8.00%
Paid preferred stock value (in Dollars)						$ 3,000
Number of warrant to purchase shares				2,461
Purchase price (in Dollars per share)				$ 0.01
Class A Common Stock [Member]
Equity (Details) [Line Items]
Conversion price per share (in Dollars per share)				$ 3,000
Common stock converted		35,597
Authorized common shares				78,000
Class B Common Stock [Member]
Equity (Details) [Line Items]
Common stock converted		64,402
Authorized common shares				76,503
Number of warrant to purchase shares					1,367
Purchase price (in Dollars per share)					$ 0.01

Stock Based Compensation (Details) - USD ($)	9 Months Ended	12 Months Ended
Stock Based Compensation (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Reserved shares (in Shares)	16,607,894
Stock options granted contractual term	10 years
Employee stock options on a converted basis had vested (in Shares)	2,500,000
Weighted average fair value per share (in Dollars per share)	$ 5.92	$ 2.8
Stock option awards granted	$ 27,812,078	$ 20,792,804
Weighted-average period	3 years 8 months 23 days
Total grant-date fair value	$ 1,049,999
Stock-based compensation expense	177,840
Unrecognized compensation cost	$ 1,241,163
Weighted-average period	3 years 1 month 6 days

Stock Based Compensation (Details) - Schedule of fair value of the sole stock option grants	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock Based Compensation (Details) - Schedule of fair value of the sole stock option grants [Line Items]
Expected term (in years)	4 years
Volatility		65.00%
Dividend yield	0.00%	0.00%
Minimum [Member]
Stock Based Compensation (Details) - Schedule of fair value of the sole stock option grants [Line Items]
Risk-free interest rate	7.00%	15.00%
Expected term (in years)		5 years
Volatility	60.00%
Maximum [Member]
Stock Based Compensation (Details) - Schedule of fair value of the sole stock option grants [Line Items]
Risk-free interest rate	2.80%	62.00%
Expected term (in years)		2 years
Volatility	64.00%

Stock Based Compensation (Details) - Schedule of company’s stock option activity - USD ($)	9 Months Ended
	Sep. 30, 2022
Schedule Of Company SStock Option Activity Abstract
Options Shares, Beginning	8,422,972
Weighted Average Exercise Price, Beginning	$ 6.21
Weighted Average Remaining Contractual Life in Years, Beginning	8 years 9 months 7 days
Aggregate Intrinsic Value, Beginning	$ 24,706,020
Options Shares, Granted/ Vested during the year	2,183,026
Weighted Average Exercise Price, Granted/ Vested during the year	$ 5.92
Weighted Average Remaining Contractual Life in Years, Granted/ Vested during the year	9 years 25 days
Aggregate Intrinsic Value, Granted/ Vested during the year
Options Shares, Exercised during the year	(1,637,159)
Weighted Average Exercise Price, Exercised during the year	$ 2.04
Weighted Average Remaining Contractual Life in Years, Exercised during the year	5 years 5 months 19 days
Aggregate Intrinsic Value, Exercised during the year
Options Shares, Cancelled during the year	(706,642)
Weighted Average Exercise Price, Cancelled during the year	$ 7.71
Weighted Average Remaining Contractual Life in Years, Cancelled during the year	8 years 9 months 25 days
Aggregate Intrinsic Value, Cancelled during the year
Options Shares, Ending	8,262,197
Weighted Average Exercise Price, Ending	$ 7.04
Weighted Average Remaining Contractual Life in Years, Ending	8 years 8 months 19 days
Aggregate Intrinsic Value, Ending	$ 22,950,815
Options Shares, Options vested and exercisable	2,502,717
Weighted Average Exercise Price, Options vested and exercisable	$ 6.11
Weighted Average Remaining Contractual Life in Years, Options vested and exercisable	8 years 3 months 18 days
Aggregate Intrinsic Value, Options vested and exercisable	$ 10,010,617

Stock Based Compensation (Details) - Schedule of activity under RSUs	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Schedule Of Activity Under Rsus Abstract
RSUs, Balance \| shares	50,192
Weighted- Average Grant Date Fair Value Per RSU, Balance \| $ / shares	$ 9.97
RSUs, Granted \| shares	146,853
Weighted- Average Grant Date Fair Value Per RSU, Granted \| $ / shares	$ 7.15
RSUs Vested during the year \| shares	(16,645)
Weighted- Average Grant Date Fair Value Per RSU Vested during the year \| $ / shares	$ 9.97
RSUs, Forfeited \| shares
Weighted- Average Grant Date Fair Value Per RSU, Forfeited \| $ / shares
RSUs, Balance \| shares	180,400
Weighted- Average Grant Date Fair Value Per RSU, Balance \| $ / shares	$ 7.67
RSUs, Vested and unissued \| shares
Weighted- Average Grant Date Fair Value Per RSU, Vested and unissued \| $ / shares
RSUs, Non-vested \| shares	180,400
Weighted- Average Grant Date Fair Value Per RSU, Non-vested \| $ / shares	$ 7.67

Leases (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
Leases (Details) - USD ($)	Jan. 01, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases [Abstract]
Expiring Date				2026
Estimated borrowing rate	6.00%
Operating lease expense		$ 960,807	$ 570,781	$ 2,380,857	$ 1,702,515
Operating lease payment		626,188	519,716	1,517,541	1,446,067
Financing lease payments		672,975	725,233	2,146,857	1,972,283
Finance lease agreement with liability				8,945,489		$ 10,139,410
Accumulated depreciation expense		9,662,686		9,662,686		$ 7,095,242
Depreciation expense		$ 873,713	$ 752,313	2,391,989	$ 2,109,770
Amount of gains from lease				$ 1,400,000

Leases (Details) - Schedule of comprise lease expenses - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule Of Comprise Lease Expenses Abstract
Operating lease expense	$ 626,188	$ 508,128	$ 1,517,541	$ 1,446,067
Short-term lease expense	334,619	62,653	863,316	256,448
Total lease cost	960,807	570,781	2,380,857	1,702,515
Finance lease payment	672,975	717,891	2,146,857	1,972,283
Short-term lease payment
Total lease payments	$ 672,975	$ 717,891	$ 2,146,857	$ 1,972,283

Leases (Details) - Schedule of company’s operating leases were recorded in the condensed consolidated balance sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets
Lease right-of-use assets	$ 8,185,547	$ 4,195,682
Total lease assets	8,185,547	4,195,682
Current liabilities:
Lease liability - current portion	2,059,278	1,461,335
Noncurrent liabilities:
Lease liability, net of current portion	6,406,246	2,980,946
Total lease liability	8,465,524	4,442,281
Assets
Lease right-of-use assets	9,421,196	9,307,113
Total lease assets	9,421,196	9,307,113
Current liabilities:
Lease liability - current portion	2,858,968	3,271,990
Noncurrent liabilities:
Lease liability, net of current portion	6,086,521	6,867,420
Total lease liability	$ 8,945,489	$ 10,139,410

Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate	Sep. 30, 2022
Schedule Of Weighted Average Remaining Lease Term And The Weighted Average Discount Rate Abstract
Weighted average remaining lease term (in years) - operating leases	5 years 2 months 19 days
Weighted average discount rate - operating leases	6.00%
Weighted average remaining lease term (in years) - finance leases	3 years 11 months 1 day
Weighted average discount rate - finance leases	6.01%

Leases (Details) - Schedule of future minimum lease payments under the operating leases	Sep. 30, 2022 USD ($)
Leases (Details) - Schedule of future minimum lease payments under the operating leases [Line Items]
2022, remaining	$ 676,878
2023	2,375,470
2024	1,880,974
2025	1,897,247
2026	1,499,654
2027 and thereafter	1,418,692
Total future minimum lease payments	9,748,915
Less effects of discounting	(1,283,391)
Present value of future minimum lease payments	8,465,524
Operating Leases [Member]
Leases (Details) - Schedule of future minimum lease payments under the operating leases [Line Items]
2022, remaining	676,878
2023	2,375,470
2024	1,880,974
2025	1,897,247
2026	1,499,654
2027 and thereafter	1,418,692
Total future minimum lease payments	9,748,915
Less effects of discounting	(1,283,391)
Present value of future minimum lease payments	8,465,524
Finance Leases [Member]
Leases (Details) - Schedule of future minimum lease payments under the operating leases [Line Items]
2022, remaining	878,626
2023	3,127,590
2024	2,398,030
2025	2,095,826
2026	1,185,433
2027 and thereafter	274,974
Total future minimum lease payments	9,960,479
Less effects of discounting	(1,014,990)
Present value of future minimum lease payments	$ 8,945,489

Other Expense (Details)	9 Months Ended
Other Expense (Details)	Sep. 30, 2022 USD ($)
Other Income and Expenses [Abstract]
Company recognized other income	$ 1.8

Related Party Transactions (Details) - USD ($)	6 Months Ended		9 Months Ended
Related Party Transactions (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transactions [Abstract]
Commission payments	$ 261,185	$ 186,075	$ 704,593	$ 476,293
Subcontractor payments	118,645	$ 92,359	364,844	$ 592,417
Accounts payable	$ 118,604		$ 118,604
Due to related parties					$ 94,636

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense/(benefit)	$ 401,906	$ 604,608	$ 1,163,755	$ 613,531

Legal Proceedings (Details) - USD ($)	May 06, 2021	Sep. 30, 2022	Dec. 31, 2021
Legal Proceedings [Abstract]
Recorded liability		$ 1,000,000	$ 1,000,000
Administrative costs and fees	$ 1,000,000

Risk and Uncertainties (Details) - USD ($)	1 Months Ended	9 Months Ended
Risk and Uncertainties (Details) - USD ($)	Apr. 30, 2020	Sep. 30, 2022	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Proceeds from payments received	$ 2,397,024
Repayment terms		11 months
Medicare payments percentage		25.00%
Medicare accelerated payments, description		At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid.
Medicare accelerated payments		$ 975,415	$ 975,415

Subsequent Events (Details)	9 Months Ended
Subsequent Events (Details)	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent events description	On November 1, 2022, the Company entered into a revolving loan and security agreement with two banks, with one bank as the administrative agent (the “Lenders”), with a maximum revolving advance amount of $90,000,000. The revolving facility includes the ability for the Company to request an increase to the commitment by an additional up to $50,000,000, though no Lender (nor the Lenders collectively) are obligated to increase their respective commitments. Borrowings under the revolving facility bear interest at a per annum rate equal to, (i) at the Company’s option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins are 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and will be updated based on the consolidated net leverage ratio reported in the compliance certificate.